Member Info for FrankMass

Flip between viewing this as signal "still in the funding market", or more positively to gain greater analyst exposure for future coverage.

For info.

Seaport Therapeutics to Participate in Upcoming Investor Conferences in February and March – Seaport Therapeutics https://share.google/OJckBLoAWXZQmWMl4

The jack in the box is Tang.

....pressuring a cash rich zombie to shift from dilutive financing to strategic exit.

Time will tell.

Buying bricks would be more engaging than following this stock. Literally nothing to say on or off market. Yes yes one day "it will fly". Only problem is dying of boredom or apathy before "something happens".

Good luck anyways.

Dallo - all public statements refer to securing funding. If they were going to fund it, they would have announced and got on with it.

If they fail in this regard, a sher cash call would be a catastrophic move in terms of discount and credibility.

.....too many time refs there! Money and sufficient time needed to implement trial design,.logistics etc to meet their self imposed deadline.

If you look at the Corp Presentation, funding H1, Phase 3, H1.

Time is ticking. They need time to establish the trial.to.meet that timeline.

....and just to add: if they have any serious intent for Celea Phase 3 to start by mid '26, PTTC had better be close to closing somethg out otherwise this is going to get delayed and. ..... shorted.

Clock ticking.

The funding market appears to be in decently rude health for prospects, so let's hope PRTC does not prove to be too contrarian.

Healthcare Investment | January Round-Up 2026 https://share.google/8S7fboFdq79f8SuQ9

"De-risked innovation" in oncology focus.

Surge in strategic partnerships.

Robert Lynne was first announced as interim CEO 210 days ago.

The share price has fallen approx 5p since that day.

Going nowhere under current set up.

Thank you for your attention.

CFO there apparently sold entire shareholding last month. Funny that.

Zombie listed company.

This has no business being publicly traded.

Seems stable, not a lot of volume, bid-offer stretched am, settles down, mid morning incremental rise and sustained into pm more often than not. So we wait and see.

BMS CEO at JPM, passing reference to Cobenfy neuroscience potential within article below in terms of their suite of substantial revenue generators.

Dallo,...... with you on the sensitivity of what crystallises over the next few weeks.

JP Morgan 2026: Bristol Myers Squibb Focuses on the Next Decade | PharmExec https://share.google/P4zR5qMVTy1OhBHKh

Worth a read on overall market and JPM event - includes an interesting observation on Phase 2 IPO companies and stock trading levels.

On biotech’s biggest stage, renewed excitement gets a stress test | BioPharma Dive https://share.google/SRZKwvXsTsRh5KSus

Quite the sales pitch. Not exactly many audience questions and didn't think the chemistry innovation v merely having a knack for choosing right patient cohort was answered terribly convincingly. But made a good fist of trying to sell hub and spoke and residual IP value post spin off. We ll see.

Without any update on a search or or going perm or other internal changes or resignations being announced or occurring, it makes me envisage a big fat "for sale" sign. Heading to six months of this. And house brokers doing what. On the block or something more sinister, though I can't quite fathom that at all.

The AGM RNS looks odd, but it's ticking a corporate governance code deadline (before the 6 months deadline) due to significant anti vote by shareholders. It's housekeeping.

I m not sure what to make of this ex a short term exit scenario. Unless some news comes through in terms of broker notes as part of a more strategic play around the stock and elusive "shareholder value", but with a large static institutional hold and little free market that seems a little farfetched given history.

I can't now escape the conclusion that we have an interim CEO and Chair and the resolution of that one way or another will dictate everything.

.....interview with gallop pharma ceo.......https://share.google/fVkYdK5AcBJH3ujN2

ASH - 6-9 Dec